FDA Drug Safety Podcast for Healthcare Professionals: Safety review update of Recombinant Human Growth Hormone (somatropin) and possible increased risk of death

On August 4, 2011, the Food and Drug Administration issued a Drug Safety Communication updating the public about its ongoing safety review of recombinant human growth hormone, or somatropin, and possible increased risk of death.